Page 14 - Central Drug Authority Annual Report 2021
P. 14
CHAPTER 1. BACKGROUND AND STRATEGIC OVERVIEW
1. BACKGROUND TO THE NDMP 2019 – 2024
7KH 3UHYHQWLRQ RI DQG 7UHDWPHQW IRU 6XEVWDQFH $EXVH $FW RWKHU FKURQLF GLVHDVH 7KLV QHFHVVLWDWHG EHWWHU HQJDJHPHQW
$FW RI SURYLGHV D UHJXODWRU\ IUDPHZRUN IRU RI SHRSOH ZKR XVH GUXJV 3:8'V LQ WKH GHVLJQ RI SROLFLHV
WKH PDQDJHPHQW RI VXEVWDQFH DEXVH LQ WKH FRXQWU\ 6HFWLRQ DQG SURJUDPPHV WKDW DIIHFW WKHP LQFOXGLQJ WKH 1'03
I SURYLGHV IRU WKH HVWDEOLVKPHQW RI WKH &'$ DQG JLYHV LW
D PDQGDWH WR IDFLOLWDWH WKH LQLWLDWLRQ DQG SURPRWLRQ RI 7KH &HQWUDO 'UXJ $XWKRULW\ WKHUHIRUH FRQGXFWHG FRQVXOWD-
PHDVXUHV WR FRPEDW WKH DEXVH RI VXEVWDQFHV LQ WKH FRXQWU\ WLRQV ZLWK JURXSV RI 3HRSOH :KR 8VH 'UXJV 3:8'V DQG
,Q WHUPV RI 6HFWLRQ K WKH &'$ LV HQMRLQHG WR VXEPLW DQ 3HRSOH :KR ,QMHFW 'UXJV 3:,'V DV ZHOO DV SURIHVVLRQDOV LQ
$QQXDO 5HSRUW WKDW SURYLGHV D FRPSUHKHQVLYH GHVFULSWLRQ RI ERWK WKH SXEOLF DQG SULYDWH VHFWRU FRYHULQJ D YDULHW\ RI
KRZ WKH FRXQWU\ LV FRPEDWLQJ VXEVWDQFH DEXVH 7KH &'$ LQWHUHVWV LQ WKH ˉHOG RI VXEVWDQFH DEXVH 7KH PRGHO LV D
PXVW WKHUHIRUH VXSSRUW LQLWLDWLYHV DQG HIIRUWV RI UHOHYDQW UDGLFDO GHSDUWXUH IURP SUHYLRXV DSSURDFKHV DV LW LQFRUSR-
VWDNHKROGHUV WR UHGXFH WKH VFRXUJH RI VXEVWDQFH DEXVH DQG UDWHV KHDOWK FRQFHUQV DQG UHGXFWLRQ RI KDUP DV SDUW RI WKH
UHODWHG VRFLDO LOOV DQG HQVXUH WKDW WKHUH LV FRKHUHQFH QHZ SDUDGLJP VKLIW 7KLV PRGHO LV FXUUHQWO\ EHLQJ WHVWHG LQ
LQWHJUDWLRQ DQG FROODERUDWLRQ EHWZHHQ VXFK VWDNHKROGHUV LQ VHOHFWHG SURYLQFHV
WKH PDQDJHPHQW RI VXEVWDQFH DEXVH LQ WKH FRXQWU\
7KH UHSRUW RXWOLQHV WKH IROORZLQJ
This report covers the period 01 April 2020 to 31 March $YDLODEOH GDWD RQ WKH QDWXUH DQG H[WHQW RI VXEVWDQFH
2021. XVH DQG DEXVH DQG WKH UHODWHG KDUP DQG QHJDWLYH
7KH $QQXDO 5HSRUW PHDVXUHV DFKLHYHPHQWV RI LPSDFW LW KDV RQ WKH IDEULF RI VRFLHW\ LQ WKH FRXQWU\
the goals of the National Drug Master Plan (NDMP) 7KH &'$ FRQWLQXHV WR VHHN WKH EHVW RI WKH ODWHVW
FUHGLEOH SXEOLVKHG SHHU UHYLHZHG UHVHDUFK WR
DPLG WKH &29,' SDQGHPLF LGHQWLˉHV XQGHUVWDQG WUHQGV LGHQWLI\ DQ\ FKDOOHQJHV DQG
FKDOOHQJHV DQG PDNHV UHFRPPHQGDWLRQV WR VWDNHKROGHUV RQ REWDLQLQJ JXLGDQFH LQ DFKLHYLQJ WKH VHW REMHFWLYHV
FROOHFWLYH LQLWLDWLYHV WKDW ZLOO SURPRWH WKHVH JRDOV 7KH DQG VHUYLQJ WKH FRPPXQLW\
1'03 LV D EOXHSULQW IRU WKH PDQDJHPHQW RI VXEVWDQFH DEXVH .H\ LQVWLWXWLRQDO DUUDQJHPHQWV RI WKH &'$ VXFK DV
WKURXJK VXSSO\ UHGXFWLRQ GHPDQG UHGXFWLRQ DV ZHOO DV WKH FRPSRVLWLRQ DQG IXQFWLRQV RI PHPEHUV WKH
WUHDWPHQW DQG KDUP UHGXFWLRQ VWUDWHJLHV LQ WKH FRXQWU\ 7KLV VHFUHWDULDW DQG VXSSRUW VWUXFWXUHV QDPHO\ QDWLRQDO
UHSRUW RXWOLQHV DFKLHYHPHQWV LQ FRXQWHULQJ VXEVWDQFH DEXVH GHSDUWPHQWV UHSUHVHQWHG LQ WKH &'$ 3URYLQFLDO
LQ OLQH ZLWK WKH LQWHJUDWHG DQG EDODQFHG DSSURDFK WR XSURRW 6XEVWDQFH $EXVH )RUXPV 36$)V DQG /RFDO 'UXJ
VXEVWDQFHV RI DEXVH LQ FRPPXQLWLHV WKURXJK VHYHQ JRDOV $FWLRQ &RPPLWWHHV /'$&
QDPHO\ &ROODERUDWLRQ ZLWK UHOHYDQW 6RXWK $IULFDQ DQG
'HPDQG 5HGXFWLRQ LQWHUQDWLRQDO DJHQFLHV LQFOXGLQJ WKH 8QLWHG 1DWLRQV
2IˉFH RQ 'UXJV DQG &ULPH 812'& WKH
6XSSO\ 5HGXFWLRQ ,QWHUQDWLRQDO 1DUFRWLFV &RQWURO %RDUG ,1&% DQG WKH
$FFHVV WR 'UXJV IRU 0HGLFDO 3XUSRVHV &RPPLVVLRQ RQ 1DUFRWLF 'UXJV &1' WKDW SURYLGH
&RQWURO RI 1HZ 3V\FKRDFWLYH 6XEVWDQFHV OHDGHUVKLS DQG VWUHQJWKHQ ORFDO LQLWLDWLYHV DQG
*RYHUQDQFH DQG /HDGHUVKLS HIIRUWV WRZDUGV FRPEDWLQJ VXEVWDQFH DEXVH LQ WKH
6WUHQJWKHQLQJ 'DWD &ROOHFWLRQ DQG 5HVHDUFK FRXQWU\
6WLPXODWH 6XVWDLQDEOH (FRQRPLF *URZWK $SSURDFKHV 3HUIRUPDQFH UHSRUWV RI NH\ QDWLRQDO GHSDUWPHQWV
WKDW DUH PHPEHUV RI WKH &'$ DQG GHULYH WKHLU
7KH LQLWLDWLYHV DQG HIIRUWV RI VWDNHKROGHUV ZHUH DLPHG DW PDQGDWH IURP WKH 3UHYHQWLRQ RI DQG 7UHDWPHQW IRU
FRQWULEXWLQJ WRZDUGV DFKLHYLQJ WKH RXWFRPHV RI WKH 1'3 6XEVWDQFH $FW $FW 1R RI DV ZHOO DV
0HGLXP 7HUP 6WUDWHJLF )UDPHZRUN QDPHO\ OHJLVODWLRQ DSSOLFDEOH WR WKRVH VHFWRU GHSDUWPHQWV
5HGXFHG OHYHO RI SRYHUW\ DV DUWLFXODWHG LQ WKH 1'03
5HGXFHG OHYHO RI LQHTXDOLW\ 7KH SHUIRUPDQFH UHSRUWV RI WKH 3URYLQFLDO 6XEVWDQFH
5HGXFHG VRFLDO LOOV LPSURYHG ZHOO EHLQJ RI FKLOGUHQ $EXVH )RUXPV PHDVXUHG DJDLQVW WKH JRDOV DQG
RXWFRPHV VWLSXODWHG LQ WKH 1'03 DQG
IDPLOLHV DQG FRPPXQLWLHV $ JORVVDU\ RI VWDQGDUGLVHG DJUHHG GHˉQLWLRQV DQG
(PSRZHUHG UHVLOLHQW LQGLYLGXDOV IDPLOLHV DQG NH\ WHUPLQRORJ\ WKDW LV XWLOLVHG LQ VXEVWDQFH DEXVH
VXVWDLQDEOH FRPPXQLWLHV UHODWHG LQWHUYHQWLRQ FLUFOHV WR DYRLG
,PSURYHG VHFWRU FDSDELOLW\ PLVFRPPXQLFDWLRQ DQG SURPRWH FRQVLVWHQF\ 7KH
,Q WKH ODVW UHSRUW LW ZDV LQGLFDWHG WKDW GXULQJ WKH UHYLHZ RI GHˉQLWLRQV DUH GHULYHG IURP FODVVLˉFDWLRQ V\VWHPV RI
WKH 1'03 GUDVWLF PHDVXUHV ZHUH WDNHQ WR DPRQJ RWKHUV WKH 7HQWK 5HYLVLRQ RI WKH
LQFRUSRUDWH WKH UHVROXWLRQV RI WKH 8QLWHG 1DWLRQV *HQHUDO ,QWHUQDWLRQDO &ODVVLˉFDWLRQ RI 'LVHDVHV DQG +HDOWK
$VVHPEO\ 6SHFLDO 6HVVLRQ LQ $SULO ZKHUHLQ FRXQWULHV 3UREOHPV ,&' :+2 DQG WKH 'LDJQRVWLF
ZHUH HQFRXUDJHG WR WUHDW 6XEVWDQFH 8VH 'LVRUGHUV OLNH DQ\ DQG 6WDWLVWLFDO 0DQXDO RI 0HQWDO 'LVRUGHUV '60 9
RI WKH $PHULFDQ 3V\FKLDWULF $VVRFLDWLRQ DV
DGRSWHG E\ WKH :+2 DQG 81(6&2
12 Annual Report 2020/2021 Central Drug Authority
